Table 1. Clinical laboratory findings at the time of admission to our facility.
| Hematological tests | |
|---|---|
| White blood cell (µL) | 9.9×103 |
| Red blood cell (µL) | 275×104 |
| Hemoglobin (g/dL) | 8.8 |
| Platelet (µL) | 86×103 |
| Reticulocyte count (µL) | 13.4×104 |
| Red blood cell fragments (RBC) | 3/1,000 |
| Laboratory investigation | |
| Total serum protein (g/dL) | 6.4 |
| Albumin (g/dL) | 4.0 |
| Urea nitrogen (mg/dL) | 84.6 |
| Creatinine (mg/dL) | 11.7 |
| Estimated glomerular filtration rate (mL/min/1.732) | 5 |
| Uric acid (g/dL) | 11.6 |
| Sodium (mmol/L) | 138 |
| Potassium (mmol/L) | 2.6 |
| Chloride (mmol/L) | 98 |
| Corrected calcium (mg/dL) | 8.7 |
| Phosphorus (mg/dL) | 5.0 |
| Total cholesterol (mg/dL) | 242 |
| Low-density lipoprotein cholesterol (mg/dL) | 156 |
| Aspartate aminotransferase (U/L) | 16 |
| Alanine aminotransferase (U/L) | 9 |
| γ-glutamyl transpeptidase (U/L) | 9 |
| Lactate dehydrogenase (U/L) | 749 |
| Alkaline phosphatase (U/L) | 124 |
| Total bilirubin (mg/dL) | 2.51 |
| Direct bilirubin (mg/dL) | 0.29 |
| Glucose (mg/dL) | 119 |
| Hemoglobin A1c (%) | 4.0 |
| C-reactive protein (mg/dL) | 1.42 |
| Brain natriuretic peptide (pg/mL) | 2,277 |
| Ferritin (ng/mL) | 354.9 |
| Haptoglobin (mg/dL) | < 10 |
| ADAMTS13 activity (%) | 67 |
| Adrenalin (pg/mL) | 236 |
| Noradrenaline (pg/mL) | 1,968 |
| Plasma aldosterone concentration (pg/mL) | 799 |
| Plasma renin activity (ng/mL/h) | ≥ 20 |
| Immunological study | |
| Immunoglobulin G (mg/dL) | 789 |
| Immunoglobulin A (mg/dL) | 254 |
| Immunoglobulin M (mg/dL) | 48 |
| Complement component 3 (mg/dL) | 78 |
| Complement component 4 (mg/dL) | 28.5 |
| Total hemolytic complement (mg/dL) | 55.5 |
| Antinuclear antibody | < 40 |
| Rheumatoid factor (IU/mL) | < 5.0 |
| Proteinase 3-anti neutrophil cytoplasmic antibody (U/mL) | < 1.0 |
| Myeloperoxidase-anti neutrophil cytoplasmic antibody (U/mL) | < 1.0 |
| Anti-glomerular basement membrane antibody (U/mL) | < 2 .0 |
| Anti-topoisomerase I antibody | Negative |
| Anti-centromere antibody | Negative |
| Anti-RNA polymerase III antibody | Negative |
| Direct Coombs test | Negative |
| Indirect Coombs test | Negative |
| Infection related survey | |
| Hepatitis B surface antigen | Negative |
| Hepatitis B surface antibody | Negative |
| Hepatitis B core antibody | Negative |
| Hepatitis C antibody | Negative |
| Human immunodeficiency virus antibody | Negative |
| Coagulation tests | |
| Prothrombin time-international normalized ratio | 1.22 |
| Activated partial thromboplastin time (s) | 29.3 |
| Control (s) | 27.4 |
| Fibrinogen (mg/dL) | 487 |
| Fibrinogen degradation product (µg/mL) | 4.10 |
| D-dimer (µg/mL) | 0.91 |
| Arterial blood gas analysis (O2 2 L×min) | |
| pH | 7.497 |
| Partial pressure of oxygen (mmHg) | 80.8 |
| Partial carbon dioxide pressure (mmHg) | 27.8 |
| Bicarbonate (mmol/L) | 20.9 |
| Base excess (mmol/L) | –1.5 |
| Urinalysis | |
| pH | 5.5 |
| Protein (0.17g/24h) | 2+ |
| Blood (1 – 4 RBCs/HPF) | 1+ |
| Glucose | – |
| White blood cell (per HPF) | < 1 |
| β2 macroglobulin (µg/L) | 4,190 |
| N-acetylglucosamine (U/L) | 13.3 |
| Granular casts (per WF) | 20 – 29 |
| Waxy casts (per WF) | 5 – 9 |
ADAMTS13 = a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13; HPF = high-power field; WF = whole field.